Nicholls CJ - Search Results

1

Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.

Sullivan SD, Freemantle N, Gupta RA, Wu J, Nicholls CJ, Westerbacka J, Bailey TS. Sullivan SD, et al. Among authors: nicholls cj. Endocrinol Diabetes Metab. 2022 Jan;5(1):e00306. doi: 10.1002/edm2.306. Epub 2021 Nov 22. Endocrinol Diabetes Metab. 2022. PMID: 34807513 Free PMC article.

2

Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.

Sullivan SD, Nicholls CJ, Gupta RA, Menon AA, Wu J, Westerbacka J, Bosnyak Z, Frias JP, Bailey TS. Sullivan SD, et al. Among authors: nicholls cj. Diabetes Obes Metab. 2019 Sep;21(9):2123-2132. doi: 10.1111/dom.13793. Epub 2019 Jun 21. Diabetes Obes Metab. 2019. PMID: 31144445 Free PMC article.

3

Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting.

Zhou FL, Nicholls C, Xie L, Wang Y, Vaidya N, Meneghini LF. Zhou FL, et al. Endocrinol Diabetes Metab. 2019 Jun 14;2(3):e00073. doi: 10.1002/edm2.73. eCollection 2019 Jul. Endocrinol Diabetes Metab. 2019. PMID: 31294087 Free PMC article.

4

Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.

Escalada J, Bonnet F, Wu J, Bonnemaire M, Gupta S, Cambron-Mellott JM, Nicholls C, Müller-Wieland D. Escalada J, et al. Adv Ther. 2020 Sep;37(9):3863-3877. doi: 10.1007/s12325-020-01436-5. Epub 2020 Jul 17. Adv Ther. 2020. PMID: 32681460 Free PMC article.

5

How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?

Mauricio D, Westerbacka J, Nicholls C, Wu J, Gupta R, Eliasson B. Mauricio D, et al. Diabetes Obes Metab. 2021 Mar;23(3):838-843. doi: 10.1111/dom.14264. Epub 2020 Dec 18. Diabetes Obes Metab. 2021. PMID: 33236461 Free PMC article.

6

Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.

Bailey TS, Gill J, Jones S M, Shenoy L, Nicholls C, Westerbacka J. Bailey TS, et al. Diabetes Obes Metab. 2022 Aug;24(8):1617-1622. doi: 10.1111/dom.14739. Epub 2022 May 26. Diabetes Obes Metab. 2022. PMID: 35491520 Free PMC article.

7

Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.

Polonsky WH, Giorgino F, Rosenstock J, Whitmire K, Lew E, Coudert M, Alvarez A, Nicholls C, McCrimmon RJ. Polonsky WH, et al. Diabetes Obes Metab. 2022 Dec;24(12):2364-2372. doi: 10.1111/dom.14822. Epub 2022 Aug 23. Diabetes Obes Metab. 2022. PMID: 36053820 Free PMC article.

8

Cost-effectiveness analysis of once-daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model.

Shao H, Shi L, Fonseca V, Alsaleh AJO, Gill J, Nicholls C. Shao H, et al. Diabet Med. 2023 Sep;40(9):e15112. doi: 10.1111/dme.15112. Epub 2023 May 12. Diabet Med. 2023. PMID: 37035994 Clinical Trial.

9

An exploratory analysis of the cost-effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model.

Shao H, Shi L, Fonseca V, Alsaleh AJO, Gill J, Nicholls C. Shao H, et al. Diabet Med. 2024 May;41(5):e15303. doi: 10.1111/dme.15303. Epub 2024 Mar 12. Diabet Med. 2024. PMID: 38470100 Clinical Trial.

10

Evaluation of an artificial intelligence-based medical device for diagnosis of autism spectrum disorder.

Megerian JT, Dey S, Melmed RD, Coury DL, Lerner M, Nicholls CJ, Sohl K, Rouhbakhsh R, Narasimhan A, Romain J, Golla S, Shareef S, Ostrovsky A, Shannon J, Kraft C, Liu-Mayo S, Abbas H, Gal-Szabo DE, Wall DP, Taraman S. Megerian JT, et al. Among authors: nicholls cj. NPJ Digit Med. 2022 May 5;5(1):57. doi: 10.1038/s41746-022-00598-6. NPJ Digit Med. 2022. PMID: 35513550 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page